Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Pharmacogenomics is the study of how genetic variation affects a person's response to medicines. It combines pharmacology with genomics to examine differences in drug effectiveness, metabolism, transport, targets, and adverse-effect risk. Pharmacogenomic information can help guide drug or dose selection for certain treatments. It is one part of precision medicine and does not replace other clinical information.
read more about pharmacogenomics ...Genetic variants can change enzymes that activate or break down medicines. They can also alter drug transporters, immune-response proteins, or the molecular targets on which medicines act. These differences can cause higher or lower drug exposure, reduced benefit, or a greater risk of toxicity. Diet, age, organ function, other medicines, and adherence still influence the final response.
Testing is used when evidence shows that a genetic result can help select a medicine, adjust a dose, or avoid a serious adverse reaction. Examples involve selected antidepressants, antiplatelet medicines, pain medicines, cancer treatments, and drugs associated with specific immune-mediated reactions. Testing can be performed before treatment or after an unexpected response. It is not available or clinically useful for every medicine.
A laboratory commonly analyzes DNA from blood, saliva, or cells collected with a cheek swab. The test can examine one gene, a small group of genes, or a broader panel. Results describe variants or predicted phenotypes relevant to specific drug-gene pairs. A clinician or pharmacist interprets the report using current prescribing information, guidelines, ancestry-related considerations, and the patient's complete clinical profile.
Pharmacogenomics can reduce trial-and-error prescribing and help avoid selected ineffective or harmful treatments. A result does not guarantee that a medicine will work or cause a side effect. Evidence and interpretation can change as new studies, guidelines, and drug labels become available. Testing also raises cost, access, privacy, consent, and data-management considerations.
The terms overlap and are frequently used interchangeably. Pharmacogenetics often refers to one or a few genes, while pharmacogenomics can refer more broadly to variation across the genome.
A person's inherited DNA result usually does not change, but its clinical interpretation can. New evidence can alter which medicines, doses, or recommendations are linked to a variant.
No. Many drug responses are influenced by health conditions, age, interactions, environment, and adherence as well as genetics. Only selected gene-drug relationships have sufficient evidence for clinical use.
Some results support a specific dose adjustment or alternative medicine, while others provide only additional risk information. Clinicians combine the result with symptoms, laboratory data, organ function, and other factors.
Pharmacogenomics Fact Sheet. National Human Genome Research Institute. https://www.genome.gov/about-genomics/educational-resources/fact-sheets/pharmacogenomics. Date Accessed August 6, 2026.
Pharmacogenetic Tests. MedlinePlus. https://medlineplus.gov/lab-tests/pharmacogenetic-tests/. Date Accessed August 6, 2026.
Table of Pharmacogenetic Associations. U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations. Date Accessed August 6, 2026.
CPIC Guidelines. Clinical Pharmacogenetics Implementation Consortium. https://cpicpgx.org/guidelines/. Date Accessed August 6, 2026.
Pharmacogenomics. Centers for Disease Control and Prevention. https://www.cdc.gov/genomics-and-health/pharmacogenomics/index.html. Date Accessed August 6, 2026.